Navigation Links
AdvanDx Launches Fast, 90 Minutes Protocol for All CE-IVD Marked PNA FISH(R) Tests in Europe
Date:4/27/2009

Pathogen Identification Results in 90 Minutes Direct from Positive Blood Cultures

Faster Results to Help Clinicians Improve Antibiotic Selection and Outcomes for Critical Infections

WOBURN, Mass. and VEDBAEK, Denmark, April 28 /PRNewswire/ -- AdvanDx today announced that it has launched a fast, 90 minutes protocol for all CE-IVD marked PNA FISH(R) tests in Europe. The fast protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization time from 90 minutes to 30 minutes. Clinical validation studies performed at hospitals in the United States and Europe show the two protocols to be 100% equivalent while maintaining the very high (>95%) sensitivity and specificity versus slower, conventional laboratory methods.

Since the first product launch in May 2003, AdvanDx's PNA FISH tests have provided rapid identification of bloodstream pathogens to help clinicians optimize antibiotic therapy and improve care for patients with critical infections. Clinical studies have shown that implementing PNA FISH tests reduced time to reporting of pathogen identification results by up to 48-72 hours, improved antibiotic selection for patients with bloodstream infections, reduced unnecessary antibiotic use, reduced infection related mortality rates and significantly reduced hospital bed, pharmacy and laboratory costs. (1,2,3,4) With the shortened protocol, labs will be able to provide results even faster to help clinicians further improve antibiotic prescribing and patient care.

"We are very excited to launch the shortened PNA FISH protocol in Europe," said Thais T. Johansen, President and CEO of AdvanDx. "The faster results will enable laboratories to provide this critical information sooner to clinicians, enabling them to make the most appropriate antibiotic selection and treatment decision as early as possible," Johansen concluded.

PNA FISH Diagnostic Platform Features:

  • Standard protocol with 90 min. Turn-around Time and minimal Hands-on Time
  • Close to 100% sensitivity and specificity versus conventional, slower laboratory methods
  • Molecular method requiring only a fluorescence microscope to get started
  • Identification of staphylococci, enterococci, Gram-Negative bacteria and Candida species directly from positive blood cultures
  • Fast and actionable results for 95-99% of all patients with bloodstream infections and positive blood cultures
  • Cost/Benefit and outcomes studies proving clinical utility of faster results

About PNA FISH(R)

PNA FISH tests enable microbiology labs to provide rapid and accurate identification of bloodstream pathogens directly from positive blood cultures in hours instead of days. Clinical studies show that rapid identification of bloodstream pathogens using PNA FISH tests leads to more appropriate patient therapy that saves lives and reduces unnecessary antibiotic use, patient length of stay and hospital costs.

About AdvanDx

AdvanDx is the world's leading provider of advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. AdvanDx's easy-to-use products provide fast and accurate results that enable dramatic improvements in patient care and help to save lives and reduce hospital costs.

AdvanDx's products employ standard laboratory techniques and equipment to reduce startup, implementation, technician and maintenance time, while providing fast results without sacrificing accuracy. Major medical centers, reference labs, government institutions and community hospitals throughout the United States, Europe and Asia rely on AdvanDx products as integral parts of their medical care.

For more information visit www.AdvanDx.com

References

  1. Ther Clin Risk Manag. 2008 Jun;4(3):637-40
  2. Antimicrob Agents Chemother. 2008 Oct;52(10):3558-63
  3. Poster P1382. ECCMID 2008, Barcelona, Spain
  4. J Clin Microbiol. 2006 Sep;44(9):3381-3

PN1617A


'/>"/>
SOURCE AdvanDx
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
2. Study Shows Use of AdvanDxs PNA FISH(TM) Test was Associated with an 82% Reduction in Intensive Care Unit Mortality Rates from Staphylococcus aureus Bloodstream Infections
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
6. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
9. Premier Micronutrient Launches Supplement for Hearing Health
10. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
11. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... DIEGO , Feb. 11, 2016 ... groundbreaking cell-isolation method that opens the door to ... until now have been impossible to isolate with ... to isolate specific tumor types in various stages ... genetic variants of these cells that are clinically ...
(Date:2/11/2016)... , Feb. 11, 2016  NanoViricides, Inc. (NYSE ... has entered into an agreement with the University ... drug candidates in standard animal models of ocular ... Research Director. Dr. Romanowski has extensive experience in ... --> Eric Romanowski , Research Director. ...
(Date:2/11/2016)... -- North America , Europe ... global market is expected to reach USD 20,190.1 Million by 2020 ... 10.2%. --> North America , ... The global market is expected to reach USD 20,190.1 Million by ... of 10.2%. --> According to a new market research ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... actively engaged in health and wellness best practices in the past couple of ... trend. February is American Heart Month, which acts as an exceptional opportunity to ...
(Date:2/11/2016)... ... February 11, 2016 , ... Research led by Providence Health ... common cancer screenings, especially among women. Cancer screenings are often the best way ... The study,“What Does Medicaid Expansion Mean for Cancer Screening and Prevention: Results from ...
(Date:2/10/2016)... ... 2016 , ... President Obama’s budget proposal yesterday enables the ... services via telehealth, estimated to generate more than $160 million in savings over ... years. Although there is more to be done, this represents an important ...
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly Sulaiman, certified clinical ... of therapeutic sessions to help Los Angeles-area actors cope with rejection, improve their ... series, known as “Mindfulness for Actors and Artists,” has been featured in ...
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier ... Food Bank of Eastern Michigan last Friday in order to aid in the Flint ... Midwest to include a facility located in Clio, only 15 miles away from Flint. ...
Breaking Medicine News(10 mins):